Table 1 Demographics of participants

Participants (n, %)

34

115

Age, years [median; IQR]

45 [39–56]

37 [33–44]

0.004

Males (n, %)

34 (100%)

114 (99%)

0.515

Body weight, kg [median; IQR]

58 [53–70]

62[54–69]

0.279

Body mass Index [median; IQR]

21.2 [19.4–23.3]

21.3[19.4–23.7]

0.896

Body surface area, m² [median; IQR]

1.67 [1.56–1.78]

1.72 [1.61–1.82]

0.104

CD4 cell count, cells/μL [median; IQR]

268 [143–398]

272 [151–370]

0.599

Estimated glomerular filtration rate, mL/min/1.73m² [median; IQR]

90[78–108]

100[87–114]

0.058

Participants with  HIV-1-RNA level < 50 at time of sampling (n, %)

15(44%)

39(34%)

0.233

Hypertension

2(6%)

2(2%)

0.224

Diabetes mellitus

2(6%)

1(1%)

0.129

Dyslipidemia

1(3%)

1(1%)

0.406

Hyperuricemia

2(6%)

2(2%)

0.224

AIDS (n, %)

9(26%)

38(33%)

0.277

Use of Trimethoprim/sulfamethoxazole (n, %)

6(18%)

19(17%)

0.877

Duration until measurement of plasma concentration (Median, days)

28

28

0.614

HBV infection (n, %)

1(3%)

21(18%)

0.018

HCV infection (n, %)

1(3%)

6(5%)

0.497

Treatment naïve (n, %)

33(97%)

108(94%)

0.475

Use of antiretroviral agents (n, %)

 Atazanavir/ritonavir (n, %)

14(41%)

41(36%)

0.558

 Lopinavir/ritonavir (n, %)

7(21%)

26(23%)

0.803

 Darunavir/ritonavir (n, %)

8(23%)

19(17%)

0.351

 Fosamprenavir/ritonavir( n, %)

2(6%)

15(13%)

0.203

 Efavirenz (n, %)

0(0%)

3(2%)

0.457

 Raltegravir (n, %)

3(9%)

11(9%)

0.599